A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

ClinicalTrials.gov ID: NCT02443155

Public ClinicalTrials.gov record NCT02443155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.

Study identification

NCT ID: NCT02443155
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 308 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 45 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 9, 2015
Primary completion: Aug 30, 2018
Completion: Feb 26, 2019
Last update posted: Apr 8, 2021

2015 – 2019

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Novo Nordisk Investigational Site	La Jolla	California	92037	—
Novo Nordisk Investigational Site	Northridge	California	91325	—
Novo Nordisk Investigational Site	Aurora	Colorado	80045	—
Novo Nordisk Investigational Site	Miami	Florida	33136	—
Novo Nordisk Investigational Site	Orlando	Florida	32804	—
Novo Nordisk Investigational Site	Atlanta	Georgia	30318	—
Novo Nordisk Investigational Site	Lexington	Kentucky	40503	—
Novo Nordisk Investigational Site	Las Vegas	Nevada	89128	—
Novo Nordisk Investigational Site	Teaneck	New Jersey	07666	—
Novo Nordisk Investigational Site	Chapel Hill	North Carolina	27517	—
Novo Nordisk Investigational Site	Nashville	Tennessee	37203	—
Novo Nordisk Investigational Site	Houston	Texas	77079	—
Novo Nordisk Investigational Site	Mesquite	Texas	75149	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02443155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 8, 2021 · Synced Sep 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02443155 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →